Testing newer Crohn's treatments when first-line therapy didn't work well

This study looks at how well two medications—upadacitinib and risankizumab—work for people with Crohn's disease who weren't helped enough by their first treatment. The research team will follow your health for up to 18 months after you start one of these medications, reviewing your medical records and tracking how you respond. This is a real-world study, meaning researchers observe how the medication works in everyday clinical practice, not in a controlled lab setting.

When the first-line treatment for Crohn's disease doesn't control symptoms well enough, doctors need to know which newer medications work best for their patients. This study will help understand how effective these treatments are and whether they help resolve the symptoms that weren't controlled before.